Verzenio
Generic name: Abemaciclib
Drug class:
CDK 4/6 inhibitors
Usage of Verzenio
Verzenio (abemaciclib) is a prescription medicine used in combination with other cancer treatments to treat certain patients with HR-positive, HER2-negative breast cancer. It is used in adults when the cancer has progressed or has spread to other parts of the body (metastatic) after other treatments have failed. Abemaciclib belongs to a class of medications called kinase inhibitors.
Verzenio is a targeted treatment known as a CDK4/6 inhibitor. It works inside the cell to block CDK4/6 activity and help stop the growth of cancer cells.
Verzenio is used in combination with an aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor-positive, early breast cancer.
Verzenio is also used along with fulvestrant (Faslodex) to treat a certain type of hormone receptor-positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body after treatment with an antiestrogen medication such as tamoxifen.
Verzenio is also used along with anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) as a first treatment of hormone receptor-positive, advanced breast cancer or breast cancer that has spread to other parts of the body.
Verzenio is also used alone to treat a certain type of hormone receptor-positive, advanced breast cancer or breast cancer that has spread to other parts of the body in people who have already been treated with an antiestrogen medication and chemotherapy.
Abemaciclib works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
When Verzenio is used in combination with fulvestrant, tamoxifen, or an aromatase inhibitor, also read the Patient Information for the associated prescribed medicine. Ask your healthcare provider if you are not sure.
Verzenio side effects
Get emergency medical help if you have signs of an allergic reaction to Verzenio: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Abemaciclib may cause serious side effects. Call your doctor at once if you have:
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common Verzenio side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Verzenio
You should not use Verzenio if you are allergic to abemaciclib, or any of the ingredients in Verzenio tablets.
To make sure this medicine is safe for you, tell your doctor if you have ever had::
Abemaciclib may harm an unborn baby. You may need a pregnancy test to make sure you are not pregnant. Use effective birth control while using Verzenio and for at least 3 weeks after your last dose. Tell your doctor right away if you become pregnant.
It may be harder for you to get a woman pregnant while you are using this medicine.
You should not breastfeed while using this medicine and for at least 3 weeks after your last dose.
Relate drugs
- Abemaciclib
- Ibrance
- Kisqali
- Kisqali (200 mg daily-dose)
- Kisqali (400 mg daily-dose)
- Kisqali (600 mg daily-dose)
- Palbociclib
- Ribociclib
- Verzenio
How to use Verzenio
Usual Adult Dose for Breast Cancer:
IN COMBINATION WITH FULVESTRANT OR AN AROMATASE INHIBITOR: 150 mg orally 2 times a day MONOTHERAPY: 200 mg orally 2 times a day Duration of Therapy: Until disease progression or unacceptable toxicity Comments: -If using this drug in combination with fulvestrant on pre/perimenopausal women, treat these patients with a gonadotropin-releasing hormone agonist according to current clinical practice standards. -When used in combination with this drug, the recommended dose of fulvestrant is 500 mg on Days 1, 15, and 29, then once monthly thereafter; refer to the manufacturer product information for fulvestrant. Uses: -In combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer -In combination with fulvestrant for women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy -As monotherapy for adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting
Warnings
Verzenio can cause severe diarrhea, which can lead to dehydration or infection. Call your doctor right away if you have diarrhea. Drink extra fluids and start taking anti-diarrhea medicine such as loperamide (Imodium).
Abemaciclib can cause blood clots, liver problems, and even serious or fatal infections. Call your doctor right away if you have symptoms such as: fever, chills, easy bruising or bleeding, unusual tiredness, loss of appetite, right-sided upper stomach pain, chest pain, shortness of breath, rapid breathing, fast heartbeats, or pain or swelling in your arms or legs.
What other drugs will affect Verzenio
Sometimes it is not safe to use certain medicines at the same time. Some drugs can affect your blood levels of other drugs you use, which may increase side effects or make the medicines less effective.
Tell your doctor about all your other medicines, especially:
This list is not complete. Other drugs may interact with abemaciclib, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions